Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C34H36FN5O2 |
| Molecular Weight | 565.6803 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)C(N1CCN(CC1)C2=CC=C(NC(=O)C3=CC=CC=C3C4=CC=CN=C4)C=C2F)C5=CC=CC=C5
InChI
InChIKey=OVUNRYUVDVWTTE-UHFFFAOYSA-N
InChI=1S/C34H36FN5O2/c1-3-38(4-2)34(42)32(25-11-6-5-7-12-25)40-21-19-39(20-22-40)31-17-16-27(23-30(31)35)37-33(41)29-15-9-8-14-28(29)26-13-10-18-36-24-26/h5-18,23-24,32H,3-4,19-22H2,1-2H3,(H,37,41)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19953226Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/23103057 | https://www.ncbi.nlm.nih.gov/pubmed/21145691
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19953226
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/23103057 | https://www.ncbi.nlm.nih.gov/pubmed/21145691
JNJ-31020028 was shown to have high affinity for both human and rodent Y2 receptors. The antagonistic property of JNJ-31020028 for the Y2 receptor was demonstrated via inhibition of PYY-stimulated calcium response in KAN-Ts cells expressing a chimeric G protein. After subcutaneous administration, the Y2 antagonist was found to penetrate into the brain and dose dependently occupy Y2 receptor binding sites, demonstrating that the compound engaged its target in the CNS. JNJ-31020028 (15 mg/kg, s.c.) did reverse the anxiogenic effects of withdrawal from a single bolus dose of alcohol on the elevated plus-maze, confirming the anxiolytic-like properties of Neuropeptide Y2 antagonism. JNJ-31020028 has antidepressant like effects in the olfactory bulbectomized model.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4018 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19953226 |
8.07 null [pIC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y₂ receptor. | 2011-09-15 |
|
| The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety. | 2011-09 |
|
| In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor. | 2010-02 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19953226
Oral: 10 mg/kg, Intravenous: 1 mg/kg, Subcutaneous: 10 mg/kg, Intracerebroventricular: 0.3 or 1.0 nmol/rat
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19953226
JNJ-31020028 (100 nM) almost completely
inhibited [125I]PYY labeling in rat hippocampus. Full blockade was observed at 1uM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1094873-14-9
Created by
admin on Mon Mar 31 23:03:24 GMT 2025 , Edited by admin on Mon Mar 31 23:03:24 GMT 2025
|
PRIMARY | |||
|
73F8XED6YP
Created by
admin on Mon Mar 31 23:03:24 GMT 2025 , Edited by admin on Mon Mar 31 23:03:24 GMT 2025
|
PRIMARY | |||
|
25134625
Created by
admin on Mon Mar 31 23:03:24 GMT 2025 , Edited by admin on Mon Mar 31 23:03:24 GMT 2025
|
PRIMARY |
ACTIVE MOIETY